EMBASE Cardiac Update AutoAlert: EPICORE Cardiac Surgery Blogger2

Total documents retrieved: 19

Results Generated From:
Embase <1980 to 2013 Week 41>
Embase (updates since 2013-10-04)

<1>
Accession Number
2013594406
Authors
Namazi M.H. Safi M. Vakili H. Saadat H. Karimi E. Khameneh Bagheri R.
Institution
(Namazi, Safi, Vakili, Saadat, Karimi, Khameneh Bagheri) Cardiovascular
Research Center, Shahid Beheshti University of Medical Sciences, Tehran,
Iran, Islamic Republic of
Title
Comparison between intracoronary abciximab and intravenous eptifibatide
administration during primary percutaneous coronary intervention of acute
ST-segment elevation myocardial infarction.
Source
Journal of Tehran University Heart Center. 8 (3) (pp 132-139), 2013. Date
of Publication: 2013.
Publisher
Tehran Heart Center (North Kargar Street, Tehran 1411713138, Iran, Islamic
Republic of)
Abstract
Background: Administration of glycoprotein IIb/IIIa inhibitors is an
effective adjunctive treatment strategy during primary percutaneous
coronary intervention (PPCI) for ST-segment elevation myocardial
infarction (STEMI). Recent data suggest that an intracoronary
administration of these drugs can increase the efficacy of PPCI. This
study was done to find any potential difference in terms of efficacy of
administering intracoronary Abciximab vs. intravenous Eptifibatide in
primary PPCI. Methods: A total of 40 STEMI patients who underwent PPCI
within 12 hours of symptom onset were randomized to either an
intracoronary Abciximab (0.25 mug/kg) bolus or two boluses of intravenous
Eptifibatide (0.180 mug/kg) each 10 minutes. The primary end points were
enzymatic infarct size, myocardial reperfusion measured as ST-segment
resolution (STR), and post-procedural thrombolysis in myocardial
infarction (TIMI) grade flow of the infarct-related artery. The secondary
end points were intra-procedural adverse effect (arrhythmia) and no-reflow
phenomenon, in-hospital mortality, reinfarction, hemorrhage, and
post-procedural global systolic function. Results: Post-procedural TIMI
grade 3 flow was achieved in 95% and 90% of the intracoronary Abciximab
and intravenous Eptifibatide groups, respectively (p value = 0.61). The
infarct size, as assessed by the area under the curve of creatine
phosphokinase-MB in the first 48 hours after PPCI (mumol/L/hr), was
similar between the intracoronary Abciximab and intravenous Eptifibatide
groups: 6591 (interquartile range [IQR], 3006.0 to 11112.0) versus 7,294
(IQR, 3795.5 to 11803.5); p value = 0.59. Complete STR was achieved in 55%
and 45% of the intracoronary Abciximab and intravenous Eptifibatide
groups, respectively (p value = 0.87). No deaths, urgent
revascularizations, reinfarctions, or TIMI major bleeding events were
observed in either group. Conclusion: The intracoronary administration of
Abciximab was not superior to the intravenous administration of
Eptifibatide in the STEMI patients who underwent primary PCI.

<2>
Accession Number
2013594405
Authors
Forouzannia S.K. Abdollahi M.H. Mirhosseini S.J. Hadadzadeh M. Zarepur R.
Zarepur E. Beiki O. Sarebanhassanabadi M.
Institution
(Forouzannia, Abdollahi, Mirhosseini, Hadadzadeh, Zarepur, Zarepur,
Sarebanhassanabadi) Yazd Cardiovascular Research Center, Shahid Sadoughi
University of Medical Sciences, Yazd, Iran, Islamic Republic of
(Beiki) Kermanshah University of Medical Sciences, Kermanshah, Iran,
Islamic Republic of
Title
Adenosine preconditioning versus ischemic preconditioning in patients
undergoing off-pump coronary artery bypass (OPCAB).
Source
Journal of Tehran University Heart Center. 8 (3) (pp 127-131), 2013. Date
of Publication: 2013.
Publisher
Tehran Heart Center (North Kargar Street, Tehran 1411713138, Iran, Islamic
Republic of)
Abstract
Background: During off-pump coronary artery bypass (OPCAB), the heart is
subjected to ischemic and reperfusion injury. Preconditioning is a
mechanism that permits the heart to tolerate myocardial ischemia. The aim
of this study was to compare the effects of Adenosine preconditioning with
ischemic preconditioning on the global ejection fraction (EF) in patients
undergoing OPCAB. Methods: In this single-blind, randomized controlled
trial, sixty patients undergoing OPCAB were allocated into three
equally-numbered groups through simple randomization: Adenosine group,
ischemic group, and control group. The patients in the Adenosine group
received an infusion of Adenosine. In the ischemic group, ischemic
preconditioning was induced by the temporary occlusion of the left
anterior descending coronary artery twice for a 2-minute period, followed
by 3-minute reperfusion before bypass grafting of the first coronary
vessel. The control group received an intravenous infusion of 0.9% saline.
Blood samples at different times were sent for the measurement of creatine
kinase isoenzyme MB (CK-MB) and cardiac troponin I (cTnI). We also
recorded electrocardiographic indices and clinical parameters, including
postoperative use of inotropic drugs and preoperative and postoperative
EF. Results: History of myocardial infarction, hyperlipidemia, diabetes
mellitus, kidney disease, preoperative arrhythmias, and utilization of
postoperative inotrope was the same between the three groups. The
incidence of postoperative arrhythmias was not significant between the
three groups. Also, there were no significant differences in preoperative
and postoperative EF and the serum levels of enzymes (cTnI and CK-MB)
between the groups. Conclusion: Based on the findings of this study, there
was no significant difference in the postoperative EF between the groups.
Although the incidence of arrhythmias was higher in the ischemic
preconditioning group than in the other groups, the difference between the
groups did not constitute statistical significance.

<3>
[Use Link to view the full text]
Accession Number
2013617717
Authors
Bragadottir G. Redfors B. Ricksten S.-E.
Institution
(Bragadottir, Redfors, Ricksten) Department of Anesthesiology and
Intensive Care Medicine, Sahlgrenska Academy, University of Gothenburg,
Sahlgrenska University Hospital, S-413 45 Goteborg, Sweden
Title
Effects of levosimendan on glomerular filtration rate, renal blood flow,
and renal oxygenation after cardiac surgery with cardiopulmonary bypass: A
randomized placebo-controlled study.
Source
Critical Care Medicine. 41 (10) (pp 2328-2335), 2013. Date of Publication:
October 2013.
Publisher
Lippincott Williams and Wilkins (530 Walnut Street,P O Box 327,
Philadelphia PA 19106-3621, United States)
Abstract
Objectives: Acute kidney injury develops in a large proportion of patients
after cardiac surgery because of the low cardiac output syndrome. The
inodilator levosimendan increases cardiac output after cardiac surgery
with cardiopulmonary bypass, but a detailed analysis of its effects on
renal perfusion, glomerular filtration, and renal oxygenation in this
group of patients is lacking. We therefore evaluated the effects of
levosimendan on renal blood flow, glomerular filtration rate, renal oxygen
consumption, and renal oxygen demand/supply relationship, i.e., renal
oxygen extraction, early after cardiac surgery with cardiopulmonary
bypass. Design: Prospective, placebo-controlled, and randomized trial.
Setting: Cardiothoracic ICU of a tertiary center. Patients: Postcardiac
surgery patients (n = 30). INTERVENTIONS: The patients were randomized to
receive levosimendan, 0.1 mug/kg/min after a loading dose of 12 mug/kg (n
= 15), or placebo (n = 15). Measurements and Main Results: The
experimental procedure started 4-6 hours after surgery in the ICU during
propofol sedation and mechanical ventilation. Systemic hemodynamic were
evaluated by a pulmonary artery thermodilution catheter. Renal blood flow
and glomerular filtration rate were measured by the renal vein retrograde
thermodilution technique and by renal extraction of Cr-EDTA, respectively.
Central venous pressure was kept constant by colloid/crystalloid infusion.
Compared to placebo, levosimendan increased cardiac index (22%), stroke
volume index (15%), and heart rate (7%) and decreased systemic vascular
resistance index (21%), whereas mean arterial pressure was not affected.
Levosimendan induced significant increases in renal blood flow (12%, p <
0.05) and glomerular filtration rate (21%, p < 0.05), decreased renal
vascular resistance (18%, p < 0.05) but caused no significant changes in
filtration fraction, renal oxygen consumption, or renal oxygen extraction,
compared to placebo. Conclusions: After cardiac surgery with
cardiopulmonary bypass, levosimendan induces a vasodilation,
preferentially of preglomerular resistance vessels, increasing both renal
blood flow and glomerular filtration rate without jeopardizing renal
oxygenation. Due to its pharmacodynamic profile, levosimendan might be an
interesting alternative for treatment of postoperative heart failure
complicated by acute kidney injury in postcardiac surgery patients.
Copyright 2013 by the Society of Critical Care Medicine and Lippincott
Williams & Wilkins.

<4>
Accession Number
2013617165
Authors
Florescu D.F. Kalil A.C. Qiu F. Schmidt C.M. Sandkovsky U.
Institution
(Florescu, Kalil, Sandkovsky) Infectious Diseases Division, University of
Nebraska Medical Center, Omaha, NE, United States
(Florescu) Transplant Surgery Division, University of Nebraska Medical
Center, Omaha, NE, United States
(Qiu) Biostatistics Department, University of Nebraska Medical Center,
Omaha, NE, United States
(Schmidt) McGoogan Library of Medicine, Nebraska Medical Center, Omaha,
NE, United States
Title
What is the impact of hypogammaglobulinemia on the rate of infections and
survival in solid organ transplantation? A meta-analysis.
Source
American Journal of Transplantation. 13 (10) (pp 2601-2610), 2013. Date of
Publication: October 2013.
Publisher
Blackwell Publishing Ltd (9600 Garsington Road, Oxford OX4 2XG, United
Kingdom)
Abstract
Hypogammaglobulinemia has been described after solid organ transplantation
and has been associated with increased risk of infections. The aim of the
study was to evaluate the rate of severe hypogammaglobulinemia and its
relationship with the risk of infections during the first year
posttransplantation. Eighteen studies (1756 patients) that evaluated
hypogammaglobulinemia and posttransplant infections were included. The
data were pooled using the DerSimonian and Laird random-effects model. Q
statistic method was used to assess statistical heterogeneity. Within the
first year posttransplantation, the rate of hypogammaglobulinemia (IgG <
700 mg/dL) was 45% (95% CI: 0.34-0.55; Q = 330.1, p < 0.0001), the rate of
mild hypogammaglobulinemia (IgG = 400-700 mg/dL) was 39% (95% CI:
0.22-0.56; Q = 210.09, p < 0.0001) and the rate of severe
hypogammaglobulinemia (IgG < 400 mg/dL) was 15% (95% CI: 0.08-0.22; Q =
50.15, p < 0.0001). The rate of hypogammaglobulinemia by allograft type:
heart 49% (21%-78%; Q = 131.16, p < 0.0001); kidney 40% (30%-49%; Q =
24.55, p = 0.0002); liver 16% (0.001%-35%; Q = 14.31, p = 0.0002) and lung
63% (53%-74%; Q = 6.85, p = 0.08). The odds of respiratory infection (OR =
4.83; 95% CI: 1.66-14.05; p = 0.004; I² = 0%), CMV (OR = 2.40;
95% CI: 1.16-4.96; p = 0.02; I² = 26.66%), Aspergillus (OR =
8.19; 95% CI: 2.38-28.21; p = 0.0009; I² = 17.02%) and other
fungal infections (OR = 3.69; 95% CI: 1.11-12.33; p = 0.03; I²
= 0%) for patients with IgG <400 mg/dL were higher than the odds for
patients with IgG >400 mg/dL. The odds for 1-year all-cause mortality for
severe hypogammaglobulinemia group was 21.91 times higher than those for
IgG >400 mg/dL group (95% CI: 2.49-192.55; p = 0.005; I² = 0%).
Severe hypogammaglobulinemia during the first year posttransplantation
significantly increased the risk of CMV, fungal and respiratory
infections, and was associated with higher 1-year all-cause mortality.
Severe hypogammaglobulinemia during the first year posttransplantation
increases the risk of CMV, fungal and respiratory infections, and it is
associated with higher one-year all-cause mortality. See editorial by
Avery and Blumberg on page 2517. 2013 The American Society of
Transplantation and the American Society of Transplant Surgeons.

<5>
Accession Number
2013611716
Authors
Munipalle P.C. Garud T. Light D.
Institution
(Munipalle, Garud, Light) Department of General Surgery, Friarage
Hospital, Northallerton, North Yorks, United Kingdom
Title
Diaphragmatic disease of the colon: Systematic review.
Source
Colorectal Disease. 15 (9) (pp 1063-1069), 2013. Date of Publication:
September 2013.
Publisher
Blackwell Publishing Ltd (9600 Garsington Road, Oxford OX4 2XG, United
Kingdom)
Abstract
Aim: Diaphragmatic disease is rare. This review aims to increase awareness
of this condition and its management. Method: A literature search was
conducted using the key terms 'colon' or 'colonic' in combination with
'diaphragm' or 'diaphragm disease' for publications until August 2012. All
cases of colonic diaphragm syndrome were identified and the required data
were collected. Results: Forty-five cases of colon diaphragm disease were
included. The highest incidence was in the seventh decade of life, with a
female preponderance (40F:5M). Most patients presented with chronic
(median 3 months) and multiple symptoms. The median use of nonsteroidal
anti-inflammatory drugs (NSAIDs) was 5 years including diclofenac as the
most commonly used NSAID. Colonoscopy was the most informative
investigation and the ascending colon was the most common site of
diaphragm disease. Nearly two-thirds of the patients were treated by
discontinuing NSAID treatment combined with other forms of treatment,
mostly surgery. Conclusion: Diaphragm disease of the colon is a rare
condition associated with long-term use of NSAIDs with a range of
presentations and symptoms. Based on this review, when colon diaphragm
disease is diagnosed we would recommend a trial cessation of NSAIDs.
Therapeutic endoscopic techniques should be considered but surgery may be
required for definitive treatment. 2013 The Association of Coloproctology
of Great Britain and Ireland.

<6>
Accession Number
2013604384
Authors
Nozue T. Fukui K. Yamamoto S. Kunishima T. Umezawa S. Onishi Y. Tohyama S.
Takeyama Y. Morino Y. Yamauchi T. Hibi K. Sozu T. Terashima M. Michishita
I.
Institution
(Nozue, Michishita) Division of Cardiology, Department of Internal
Medicine, Yokohama Sakae Kyosai Hospital, Yokohama, Japan
(Fukui) Department of Cardiology, Kanagawa Cardiovascular and Respiratory
Center, Yokohama, Japan
(Yamamoto) Department of Cardiology, Tsurumi Nishiguchi Hospital,
Yokohama, Japan
(Kunishima) Fourth Department of Internal Medicine, Mizonokuchi Hospital,
Teikyo University School of Medicine, Kawasaki, Japan
(Umezawa, Onishi) Department of Cardiology, Hiratsuka Kyosai Hospital,
Hiratsuka, Japan
(Tohyama) Department of Cardiology, Yokohama Seamen's Insurance Hospital,
Yokohama, Japan
(Takeyama) Division of Cardiology, Showa University Fujigaoka
Rehabilitation Hospital, Yokohama, Japan
(Morino) Department of Cardiology, Iwate Medical University, Morioka,
Japan
(Yamauchi) Department of Cardiology, Tokyo Women's Medical University,
Tokyo, Japan
(Hibi) Division of Cardiology, Yokohama City University Medical Center,
Yokohama, Japan
(Sozu) Department of Biostatistics, Kyoto University School of Public
Health, Kyoto, Japan
(Terashima) Cardiovascular Imaging Center, Toyohashi, Japan
Title
C-reactive protein and future cardiovascular events in statin- treated
patients with angina pectoris: The extended TRUTH study.
Source
Journal of Atherosclerosis and Thrombosis. 20 (9) (pp 717-725), 2013. Date
of Publication: 2013.
Publisher
Japan Atherosclerosis Society (2-20-15 Shinbashi, Minato-ku, Tokyo
105-0004, Japan)
Abstract
The TRUTH trial demonstrated that 8-month statin therapy alters the
composition of coronary artery plaque using virtual histology
(VH)-intravascular ultrasound (IVUS). The extended TRUTH study was
conducted to evaluate the relationship between changes in coronary
atherosclerosis and mid-term clinical outcomes and identify the factors
associated with cardiovascular events. Methods: Of 164 patients with
angina pectoris who participated in the TRUTH trial, 119 subjects with
analyzable IVUS data at both enrollment and the 8-month follow-up were
enrolled and observed for at least two years. The primary end point was
the time to first occurrence of cardiovascular composite events, including
cardiovascular death, nonfatal myocardial infarction, nonfatal cerebral
infarction, unstable angina and ischemic-driven revascularization, except
for target lesion revascularization. Results: The frequency of reaching
the primary end point was 13% (16/119), with a mean follow-up period of
41.9+/-9.4 months. Although plaque regression and changes in plaque
composition were not associated with future cardiovascular events, the
serum high-sensitivity C-reactive protein (hs- CRP) levels at the start of
the extended TRUTH study were significantly higher in the event group than
in the event-free group (1.43 mg/L vs. 0.58 mg/L, p= 0.01). A multivariate
logistic regression analysis showed that the hs-CRP level was an
independent significant predictor of cardiovascular events (odds ratio:
1.69; 95% confidence interval: 1.14-2.50, p= 0.01). Conclusions: Coronary
artery plaque regression and changes in plaque composition during statin
therapy do not predict future cardiovascular events in patients with
angina pectoris. Instead, the serum hs-CRP level can be used as a
predictor of cardiovascular events.

<7>
Accession Number
2013604343
Authors
Lv J.-Y. Li X. Wang L. Xin S.-J.
Institution
(Lv, Wang, Li, Wang, Xin) Department of Vascular and Thyroid Surgery, The
First Affiliated Hospital of China Medical University, Shenyang 110001,
China
Title
Amiodarone for repurfusion arrhythmia after thrombolytic therapy for acute
myocardial infarction: A meta-analysis.
Source
Chinese Journal of Evidence-Based Medicine. 13 (9) (pp 1110-1115), 2013.
Date of Publication: 2013.
Publisher
West China University of Medical Science (37 Wainan Guoxue Xiang, Chengdu,
Sichuan 610041, China)
Abstract
Objective To systematically review the effectiveness of amiodarone in
treating repurfusion arrhythmia (RA) after thrombolytic therapy for acute
myocardial infarction (AMI), so as to provide high quality evidence for
formulating the rational thrombolytic therapy for AMI. Methods Randomized
controlled trails (RCTs) on amiodarone in treating RA after thrombolytic
therapy for AMI were electronically retrieved in PubMed, EMbase, The
Cochrane Library (Issue 3, 2012), CBM, CNKI, VIP and WanFang Data from
inception to January, 2013. According to the inclusion and exclusion
criteria, two reviewers independently screened literature, extracted data,
and assessed quality. Then RevMan 5.1 software was used for meta-analysis.
Results A total of 5 RCTs involving 440 patients were included. The
results of meta- analysis suggested that, compared with the blank control,
amiodarone reduced the incidence of RA after thrombolytic therapy in
treating AMI (RR=0.60, 95%CI 0.48 to 0.74, P<0.000 01) and the incidence
of ventricular fibrillation (RR=0.47, 95%CI 0.26 to 0.85, P=0.01). It
neither affected the recanalization rate of occluded arteries after
thrombolytic therapy (RR=1.00, 95%CI 0.88 to 1.15, P=0.94) nor decreased
the mortality after surgery (RR=0.33, 95%CI 0.10 to 1.09, P=0.07).
Conclusion Current evidence indicated that, amiodarone can decrease the
incidence of RA. Unfortunately, the mortality rate can't be reduced by
amiodarone. Due to the limited quality and quantity of the included
studies, more high quality studies are needed to verify the above
conclusion. 2013 Editorial Board of Chin J Evid-based Med.

<8>
Accession Number
2013604342
Authors
Yin Q. Zhang Z.-G. Ma Y.-P. Li B.-F.
Institution
(Yin) The First Affiliated Hospital, Sun Yat-sen University, Guangzhou
510080, China
(Yin, Zhang, Li) Department of Anesthesiology, Zhongshan People's
Hospital, Zhongshan 528403, China
(Ma) Hybio Pharmaceutical Co.Ltd., Shenzhen 518057, China
Title
Intracoronary glycoprotein IIb/IIIa inhibitor for patients with acute
coronary syndrome undergoing percutaneous coronary intervention: A
meta-analysis.
Source
Chinese Journal of Evidence-Based Medicine. 13 (9) (pp 1102-1109), 2013.
Date of Publication: 2013.
Publisher
West China University of Medical Science (37 Wainan Guoxue Xiang, Chengdu,
Sichuan 610041, China)
Abstract
Objective To systematically review the effectiveness and safety of
intracoronary glycoprotein IIb/IIIa inhibitors (GPIs) undergoing
percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS)
compared with intravenous administration. Methods Databases including
PubMed, EMbase, The Cochrane Library (Issue 9, 2012), Ovid, CBM, CNKI and
VIP were electronically searched for randomized controlled trials (RCTs)
about intracoronary GPIs administration versus intravenous administration
undergoing PCI for ACS from inception to September 30th, 2012. Meanwhile,
domestic relevant papers published in recent 1 year were also retrieved
manually. References of the included studies were retrieved, too.
According to the inclusion and exclusion criteria, two reviewers
independently screened literature, extracted data, and assessed the
methodologically quality of the included studies. Then, meta-analysis was
performed using RevMan 5.1 software. Results 10 RCTs involving 3 553 ACS
patients were finally included. The results of meta-analysis showed that:
compared with intravenous administration, intracoronary GPIs
administration decreased the major adverse cardiovascular event (MACE)
(OR=0.54, 95%CI 0.34 to 0.85, P=0.008). The incidences of reinfarction
(MI), revascularization (TVR) and heart failure were (OR=0.62, 95%CI 0.39
to 0.97, P=0.04), (OR=0.59, 95%CI 0.36 to 0.97, P=0.04), (OR=0.52, 95%CI
0.32 to 0.84, P=0.008), respectively. But for the mortality, there were no
significant differences between the two groups (OR=0.81, 95%CI 0.58 to
1.14, P=0.23). Intravenous administration and intracoronary administration
were alike in the incidences of mild/serious bleeding (mild: OR=0.94,
95%CI 0.75 to 1.19, P=0.63; serious: OR=1.18, 95%CI 0.76, 1.84, P=0.47).
Conclusion Compared with routine GPIs regimen of intravenous bolus,
intracoronary administration with initial dosage showed significant
benefits in clinical outcomes in ACS patients undergoing PCI, which could
not increase the incidence of bleeding. 2013 Editorial Board of Chin J
Evid-based Med.

<9>
Accession Number
2013604341
Authors
Li J.-H. Aikebaer Mula T. Inamdar K.Y.
Institution
(Li, Aikebaer, Mula, Inamdar) The First Department of Cardiac Surgery
Division, First Affiliated Hospital of Xinjiang Medical University, Urumqi
830054, China
Title
Effectiveness and safety of coronary artery bypass grafting for
unprotected left main coronary artery: A systematic review.
Source
Chinese Journal of Evidence-Based Medicine. 13 (9) (pp 1096-1101), 2013.
Date of Publication: 2013.
Publisher
West China University of Medical Science (37 Wainan Guoxue Xiang, Chengdu,
Sichuan 610041, China)
Abstract
Objective To systematically review the effectiveness and safety of
coronary artery bypass grafting (CABG) versus percutaneous coronary stent
implantation (PCI) in the treatment of patients with unprotected left main
coronary artery disease (ULMCA). Methods Databases including The Cochrane
Library (Issue 2, 2012), PubMed, EMbase, CBM, CNKI, WanFang Data and VIP
were electronically searched from inception to September 2012 for
randomized controlled trials on the effectiveness and safety of coronary
artery bypass grafting (CABG) versus percutaneous coronary stent
implantation (PCI) for ULMCA; References of the included studies were also
retrieved. Two reviewers independently screened literature according to
the inclusion and exclusion criteria, extracted data, and assessed the
methodological quality of the included studies. Then, meta-analysis was
performed using RevMan 5.0. Results Four studies were included involving 1
611 cases, of which, 802 cases are in the CABG group, while 809 cases were
in the PCI group. The results of meta-analysis showed that: comparing with
PCI, CABG significantly reduced the postoperative repeat revascularization
rate (OR=0.45, 95%CI 0.31 to 0.66, P<0.000 1), but there was no
significant difference between the two groups in reducing the myocardial
infarction incidence (OR=1.28, 95%CI 0.47 to 3.48, P=0.63), mortality rate
(OR=1.36, 95%CI 0.80 to 2.34, P=0.26), and the incidence of major adverse
cardio-cerebral vascular events (OR=0.92, 95%CI 0.66 to 1.28, P=0.61).
Conclusion This study indicates that CABG is superior to PCI in reducing
postoperative rate of target vessel revascularization. But CABG and PCI
are alike in reducing myocardial infarction incidence, mortality rate, and
the incidence of major adverse cardio-cerebral vascular events. Due to the
limited quantity and quality of the included studies, the above conclusion
needs to be verified by more high quality RCTs. 2013 Editorial Board of
Chin J Evid-based Med.

<10>
Accession Number
2013581682
Authors
Qin S.-Y. Zhou Y. Jiang H.-X. Hu B.-L. Tao L. Xie M.-z.
Institution
(Qin, Jiang, Hu, Tao, Xie) The First Affiliated Hospital of Guangxi
Medical University, Nanning, Guangxi, China
(Zhou) Minerva Foundation Institute for Medical Research, Helsinki,
Finland
Title
The Association of Diabetes Mellitus with Clinical Outcomes after Coronary
Stenting: A Meta-Analysis.
Source
PLoS ONE. 8 (9) , 2013. Article Number: e72710. Date of Publication: 16
Sep 2013.
Publisher
Public Library of Science (185 Berry Street, Suite 1300, San Francisco CA
94107, United States)
Abstract
Background:Previous studies have shown inconsistent results on the
association between diabetes mellitus (DM) and some clinical outcomes. We
conducted a meta-analysis of observational studies to assess effect of DM
on clinical outcomes after coronary stenting.Methods:We searched for
studies without language restriction in PubMed, Embase and Cochrane
library prior to 2012. The clinical outcomes including in-stent restenosis
(ISR), major adverse cardiac events (MACE), stent thrombosis (ST), target
lesion revascularization (TLR) and target vessel revascularization (TVR).
Adjusted odds ratio (OR), and the corresponding 95% confidence interval
(95% CI) was summarized.Results:55 studies involving 128,084 total
patients (38,416 DM patients and 89,668 controls) were eligible for our
analysis. Overall, there were significant associations between DM and ISR
(OR = 1.70, 95% CI: 1.53-1.89, I² = 0.0%), MACE (OR = 1.54, 95%
CI: 1.36-1.73, I² = 29.0%), ST (OR = 2.01, 95% CI: 1.36-2.97,
I² = 47.7%), TLR (OR = 1.46, 95% CI: 1.26-1.68, I² =
43.3%) as well as TVR (OR = 1.33, 95% CI: 1.17-1.51, I² =
48.3). Subgroup analysis showed that the associations were similar between
BMS and DES implantation. Moreover, there was no significant association
in the ST subgroup after 1-3 years follow-up.Conclusions:Our meta-analysis
suggests that after coronary stent implantation, DM is associated with
ISR, MACE, ST, TLR and TVR. DM appears to be a vital risk factor of these
clinical outcomes. 2013 Qin et al.

<11>
Accession Number
2013570185
Authors
Yu C.-M. Kwong J.S.W. Sanderson J.E.
Institution
(Yu, Kwong, Sanderson) Department of Medicine and Therapeutics, Chinese
University of Hong Kong, Prince of Wales Hospital, Shatin, N.T., Hong Kong
Title
Drug-eluting balloons for coronary artery disease: A meta-analysis of
randomized controlled trials.
Source
International Journal of Cardiology. 168 (1) (pp 197-206), 2013. Date of
Publication: 20 Sep 2013.
Publisher
Elsevier Ireland Ltd (P.O. Box 85, Limerick, Ireland)
Abstract
Background: Drug-eluting balloons (DEB) are attractive new alternatives to
drug-eluting stents (DES) for percutaneous coronary interventions. We
aimed to systematically review the efficacy and safety of DEB in the
treatment of coronary artery disease (CAD). Methods: MEDLINE, EMBASE and
the Cochrane Central Register of Controlled Trials (CENTRAL) were searched
in December 2011 for eligible randomized controlled trials. Primary
outcomes were target lesion revascularization (TLR), major adverse cardiac
events (MACE) and mortality. Secondary outcomes were late lumen loss,
minimal lumen diameter and binary restenosis. Results: Five studies
involving 349 patients were included. Compared to controls, DEB improved
angiographic measures with no significant effect on clinical outcomes in
the overall CAD population. There is clear superiority of DEB in patients
with in-stent restenosis in TLR (OR 0.17, 95% CI 0.07 to 0.38, p < 0.0001,
I² = 0%), MACE (OR 0.22, 95% CI 0.10 to 0.51, p = 0.0005,
I² = 13%), late lumen loss (in-stent: MD - 0.51, 95% CI - 0.73
to - 0.28, p < 0.00001, I² = 60%; in-segment: MD - 0.51, 95% CI
- 0.77 to - 0.24, p = 0.0002, I² = 72%;), minimal lumen
diameter (in-stent: MD 0.49, 95% CI 0.05 to 0.93, p = 0.03, I²
= 85%; in-segment: MD 0.49, 95% CI 0.13 to 0.86, p = 0.008, I²
= 79%) and binary restenosis (in-stent: OR 0.15, 95% CI 0.05 to 0.47, p =
0.001, I ² = 37%; in-segment: OR 0.11, 95% CI 0.05 to 0.27, p <
0.00001, I² = 17%). Conclusions: Our findings support the
current recommendation of using DEB in in-stent restenosis. Large,
well-conducted trials are essential in determining the application of DEB
in other lesion types as well as exploring device-specific efficacy and
safety profiles. 2012 Elsevier Ireland Ltd. All rights reserved.

<12>
Accession Number
23599353
Authors
Scalvini S. Zanelli E. Comini L. Dalla Tomba M. Troise G. Febo O. Giordano
A.
Institution
(Scalvini) Telemedicine Service, Fondazione Salvatore Maugeri, Institute
for Care and Scientific Research (IRCCS), Via Giuseppe Mazzini, 129-25065
Lumezzane, Brescia, Italy.
Title
Home-based versus in-hospital cardiac rehabilitation after cardiac
surgery: a nonrandomized controlled study.
Source
Physical therapy. 93 (8) (pp 1073-1083), 2013. Date of Publication: Aug
2013.
Abstract
Exercise rehabilitation after cardiac surgery has beneficial effects,
especially on a long-term basis. Rehabilitative programs with telemedicine
plus appropriate technology might satisfy the needs of performing
rehabilitation at home. The purpose of this study was to compare exercise
capacity after home-based cardiac rehabilitation (HBCR) or in-hospital
rehabilitation in patients at low to medium risk for early mortality
(EuroSCORE 0-5) following cardiac surgery. A quasi-experimental study was
conducted. At hospital discharge, patients were given the option to decide
whether to enroll in the HBCR program. Clinical examinations
(electrocardiography, cardiac echo color Doppler, chest radiography, blood
samples) of patients in the HBCR group were collected during 4 weeks of
rehabilitation, and exercise capacity (assessed using the Six-Minute Walk
Test [6MWT]) was assessed before and after rehabilitation. A group of
patients admitted to the in-hospital rehabilitation program was used as a
comparison group. Patients in the HBCR group were supervised at home by a
medical doctor and telemonitored daily by a nurse and physical therapist
by video conference. Periodic home visits by health staff also were
performed. One hundred patients were recruited into the HBCR group. An
equal number of patients was selected for the comparison group. At the end
of the 4-week study, the 2 groups showed improvement from their respective
baseline values only in the 6MWT. No difference was found in time x group
interaction. Because patients self-selected to enroll in the HBCR program
and because they were enrolled from a single clinical center, the results
of the study cannot be generalized. In patients who self-selected HBCR,
the program was found to be effective and comparable to the standard
in-hospital rehabilitative approach, indicating that rehabilitation
following cardiac surgery can be implemented effectively at home when
coadministered with an integrated telemedicine service.

<13>
Accession Number
2013571480
Authors
Xin W. Wei W. Lin Z. Zhang X. Yang H. Zhang T. Li B. Mi S.
Institution
(Xin, Zhang, Yang, Zhang, Li, Mi) Department of Cardiology, Beijing Anzhen
Hospital, Capital Medical University, Beijing, China
(Wei) Department of Pathophysiology, School of Medicine, Nankai
University, Tianjin, China
(Lin) Department of Cardiovascular Medicine, Affiliated Hospital of
Guiyang Medical College, Guizhou, China
Title
Fish Oil and Atrial Fibrillation after Cardiac Surgery: A Meta-Analysis of
Randomized Controlled Trials.
Source
PLoS ONE. 8 (9) , 2013. Article Number: e72913. Date of Publication: 10
Sep 2013.
Publisher
Public Library of Science (185 Berry Street, Suite 1300, San Francisco CA
94107, United States)
Abstract
Background:Influence of fish oil supplementation on postoperative atrial
fibrillation (POAF) was inconsistent according to published clinical
trials. The aim of the meta-analysis was to evaluate the effects of
perioperative fish oil supplementation on the incidence of POAF after
cardiac surgery.Methods:Pubmed, Embase and the Cochrane Library databases
were searched. Randomized controlled trials (RCTs) assessing perioperative
fish oil supplementation for patients undergoing cardiac surgery were
identified. Data concerning study design, patient characteristics, and
outcomes were extracted. Risk ratio (RR) and weighted mean differences
(WMD) were calculated using fixed or random effects models.Results:Eight
RCTs involving 2687 patients were included. Perioperative supplementation
of fish oil did not significantly reduce the incidence of POAF (RR = 0.86,
95%CI 0.71 to 1.03, p = 0.11) or length of hospitalization after surgery
(WMD = 0.10 days, 95% CI: 0.48 to 0.67 days, p = 0.75). Fish oil
supplementation also did not affect the perioperative mortality, incidence
of major bleeding or the length of stay in the intensive care unit.
Meta-regression and subgroup analyses indicated mean DHA dose in the
supplements may be a potential modifier for the effects of fish oil for
POAF. For supplements with DHA >1 g/d, fish oil significantly reduced the
incidence of POAF; while it did not for the supplements with a lower dose
of DHA.Conclusions:Current evidence did not support a preventative role of
fish oil for POAF. However, relative amounts of DHA and EPA in fish oil
may be important for the prevention of POAF. 2013 Xin et al.

<14>
Accession Number
2013569712
Authors
Maisano F. Franzen O. Baldus S. Schafer U. Hausleiter J. Butter C. Ussia
G.P. Sievert H. Richardt G. Widder J.D. Moccetti T. Schillinger W.
Institution
(Maisano) Scientific Institute San Raffaele, Department of Cardiac
Surgery, Hospital San Raffaele, Via Olgettina 60, 20132 Milan, Italy
(Franzen) Department of Cardiology, Rigshospitalet, Copenhagen, Denmark
(Baldus) Department of General and Interventional Cardiology, University
Heart Centre, Hamburg, Germany
(Schafer) Department of Cardiology, Asklepios Klinik St. Georg, Hamburg,
Germany
(Hausleiter) Deutsches Herzzentrum Munchen, Munich, Germany
(Butter) Heart Centre Brandenburg, Bernau/Berlin, Germany
(Ussia) Interventional Structural and Congenital Heart Disease Programme,
Ferrarotto Hospital, University of Catania, Catania, Italy
(Ussia) ETNA Foundation, Catania, Italy
(Sievert) CardioVascular Center Frankfurt, Frankfurt, Germany
(Richardt) Heart Center, Segeberger Kliniken GmbH (Academic Teaching
Hospital of the Universities of Kiel and Hamburg), Bad Segeberg, Germany
(Widder) Medizinische Hochschule, Hannover, Germany
(Moccetti) Division of Cardiology, Fondazione Cardiocentro Ticino, Lugano,
Switzerland
(Schillinger) Heart Centre, Georg-August University, Gottingen, Germany
Title
Percutaneous mitral valve interventions in the real world: Early and
1-year results from the ACCESS-EU, A prospective, multicenter,
nonrandomized post-approval study of the Mitraclip therapy in Europe.
Source
Journal of the American College of Cardiology. 62 (12) (pp 1052-1061),
2013. Date of Publication: 17 Sep 2013.
Publisher
Elsevier USA (6277 Sea Harbor Drive, Orlando FL 32862 8239, United States)
Abstract
Objectives The purpose of this article is to report early and mid-term
outcomes of the ACCESS-EU study (ACCESS-Europe A Two-Phase Observational
Study of the MitraClip System in Europe), a European prospective,
multicenter, nonrandomized post-approval study of MitraClip therapy
(Abbott Vascular, Inc., Santa Clara, California). Background MitraClip has
been increasingly performed in Europe after approval; the ACCESS-EU
registry provides a snapshot of the real-world clinical demographic data
and outcomes. Methods A total of 567 patients with significant mitral
valve regurgitation (MR) underwent MitraClip therapy at 14 European sites.
Mean logistic European System for Cardiac Operative Risk Evaluation at
baseline was 23.0 +/- 18.3; 84.9% patients were in New York Heart
Association functional class III or IV, and 52.7% of patients had an
ejection fraction <=40%. Results The MitraClip implant rate was 99.6%. A
total of 19 patients (3.4%) died within 30 days after the MitraClip
procedure. The Kaplan-Meier survival at 1 year was 81.8%. Intensive care
unit and hospital length of stay was 2.5 +/- 6.5 days and 7.7 +/- 8.2
days, respectively. Single leaflet device attachment was reported in 27
patients (4.8%). There were no MitraClip device embolizations. Thirty-six
subjects (6.3%) required mitral valve surgery within 12 months after the
MitraClip implant procedure. There was improvement in the severity of MR
at 12 months, compared with baseline (p < 0.0001), with 78.9% of patients
free from MR, severity of >2+ at 12 months. At 12 months, 71.4% of
patients had New York Heart Association functional class II or class I.
Six-min-walk-test improved 59.5 +/- 112.4 m, and
Minnesota-living-with-heart-failure score improved 13.5 +/- 20.5 points.
Conclusions In the real-world, post-approval experience in Europe,
patients undergoing the MitraClip therapy are high-risk, elderly patients,
mainly affected by functional MR. In this patient population, the
MitraClip procedure is effective with low rates of hospital mortality and
adverse events. 2013 by the American College of Cardiology Foundation
Published by Elsevier Inc.

<15>
Accession Number
2013570180
Authors
Qarawani D. Cohen A. Nahir M. Hasin Y.
Institution
(Qarawani, Nahir, Hasin) Cardiovascular Institute Bruch Padea Medical
Center, Tiberias, Israel
(Cohen) Department of Statistics, Technion, Haifa, Israel
Title
Facilitation of left ventricular function recovery post percutaneous
coronary intervention by levosimendan.
Source
International Journal of Cardiology. 168 (1) (pp 237-242), 2013. Date of
Publication: 20 Sep 2013.
Publisher
Elsevier Ireland Ltd (P.O. Box 85, Limerick, Ireland)
Abstract
Background: Efficiency of percutaneous revascularization and the utility
of levosimendan for advanced ischemic heart failure (HF) is unclear. We
examined the efficacy of revascularization and levosimendan on left
ventricular ejection fraction (LVEF) and mortality of patients admitted
with acute decompensated HF and severe left ventricular dysfunction.
Methods: A prospective case control study that enrolled 84 patients with
ischemic decompensated HF with LVEF < 35% and preserved LV wall thickness.
Group A: 42 patients whose LVEF improved post percutaneous coronary
intervention (PCI). Group B1: 22 patients whose LVEF did not improve
post-PCI alone but improved after levosimendan. Group B2: 20 patients
whose LVEF did not improve neither post-PCI nor post levosimendan.
Results: LVEF increased in group A from 22 +/- 5 to 29 +/- 5% post PCI and
continued to improve at the 6 month follow-up (36 +/- 4%). In group B1
LVEF did not improve after PCI, but increased after levosimendan from 23
+/- 4% to 32 +/- 4% and remained constant at 6 months. In group B2 LVEF 26
+/- 4% did not change following both interventions. Reverse remodeling
with a decrease in end-diastolic and end-systolic diameters was observed
only in groups A and B1. Group B2 had a dismal prognosis with 36%
in-hospital and 43% six month mortality. Groups A and B1 had a lower in
hospital (4.7%, 4.5%) and mid term (11%, 11%) mortality. Conclusion:
Improvement of LV size and function with better prognosis can be expected
in the majority of patients undergoing PCI for decompensated ischemic HF.
Levosimendan enhanced the recovery of LV function post PCI. 2012 Elsevier
Ireland Ltd. All rights reserved.

<16>
Accession Number
2013568524
Authors
Leibowitz D. Weiss A.T. Rott D. Durst R. Lotan C.
Institution
(Leibowitz, Weiss, Rott, Durst, Lotan) Heart Institute, Hadassah Hebrew
University Medical Center, Mount Scopus, Jerusalem, Israel
Title
The efficacy of cardiac shock wave therapy in the treatment of refractory
angina: A pilot prospective, randomized, double-blind trial.
Source
International Journal of Cardiology. 167 (6) (pp 3033-3034), 2013. Date of
Publication: 2013.
Publisher
Elsevier Ireland Ltd (P.O. Box 85, Limerick, Ireland)

<17>
Accession Number
2013570148
Authors
Guaricci A.I. Maffei E. Brunetti N.D. Montrone D. Di Biase L. Tedeschi C.
Gentile G. Macarini L. Midiri M. Cademartiri F. Di Biase M.
Institution
(Guaricci, Brunetti, Montrone, Di Biase, Tedeschi, Di Biase) Cardiology
Department, University of Foggia, Ospedali Riuniti Hospital, Foggia, Italy
(Maffei, Cademartiri) Cardiovascular Radiology Unit, Giovanni XXIII
Hospital, Monastier di Treviso, Italy
(Di Biase) Texas Cardiac Arrhythmia Institute, St. David's Medical Center,
Austin, TX, United States
(Gentile, Midiri) Department of Radiology, University Hospital P.
Giaccone, University of Palermo, Italy
(Macarini) Department of Diagnostic Imaging, University of Foggia,
Ospedali Riuniti Hospital, Foggia, Italy
(Cademartiri) Department of Radiology, Erasmus Medical Center University,
Rotterdam, Netherlands
Title
Heart rate control with oral ivabradine in computed tomography coronary
angiography: A randomized comparison of 7.5 mg vs 5 mg regimen.
Source
International Journal of Cardiology. 168 (1) (pp 362-368), 2013. Date of
Publication: 20 Sep 2013.
Publisher
Elsevier Ireland Ltd (P.O. Box 85, Limerick, Ireland)
Abstract
Background: Heart rate (HR) reduction is essential to achieve optimal
image quality and diagnostic accuracy with computed tomography coronary
angiography (CTCA). Administration of oral ivabradine seems to be more
effective than beta-blockade in reducing HR in patients referred for CTCA.
Methods: Two-hundred-fifty-nine consecutive patients referred for CTCA
were prospectively enrolled. Patients not receiving beta-blocker at
baseline (group 1) and those with beta-blocker therapy (group 2) were
enrolled in the study. Each group was randomized into 3 parallel arms with
1:1:1 allocation. Patients who did not receive beta-blocker at baseline:
underwent CTCA without beta blocker (n = 49), and received ivabradine 5 mg
(n = 48), or 7.5 mg ivabradine (n = 48). Patients with beta-blocker
therapy: continued with the prior beta-blocker without any dose
modification (n = 38), and received ivabradine 5 mg (n = 38), or
ivabradine 7.5 mg (n = 38). Results: HR and blood pressure were assessed
at admission (T0), immediately before CTCA (T1) and during CTCA (T2).
Administration of ivabradine 7.5 mg significantly reduced mean relative HR
at T1 and T2 (p < 0.01), the rate of patients not achieving target HR at
T1 (p < 0.001) and T2 (p < 0.01), and the percentage of patients needing
additional IV beta-blockade prior to CTCA (p < 0.01). Results remained
statistically significant even after correction for age, gender, ejection
fraction, risk factors and HR at T0, in a multivariable analysis.
Conclusions: Ivabradine 7.5 mg is more effective than ivabradine 5 mg in
increasing the rate of patients at target HR in patients referred for
CTCA. 2012 Elsevier Ireland Ltd. All rights reserved.

<18>
Accession Number
2013568592
Authors
Barthelemy O. Cayla G. Silvain J. O'Connor S.A. Bellemain-Appaix A. Beygui
F. Sideris G. Varenne O. Collet J.P. Vicaut E. Montalescot G.
Institution
(Barthelemy, Silvain, O'Connor, Bellemain-Appaix, Beygui, Collet,
Montalescot) Institut de Cardiologie, Centre Hospitalier Universitaire
Pitie-Salpetriere (AP-HP), INSERM CMR 937, Paris, France
(Cayla) Service de Cardiologie, Centre Hospitalier Universitaire Caremeau,
Nimes, France
(Sideris) Service de Cardiologie, Centre Hospitalier Universitaire
Lariboisiere (AP-HP), Paris, France
(Varenne) Service de Cardiologie, Centre Hospitalier Cochin (AP-HP),
Universite Paris Descartes, Paris, France
(Vicaut) Unite de Recherche Clinique, Centre Hospitalier Universitaire
Lariboisiere (AP-HP), France
Title
Optimal time for catheterization in NSTE-ACS patients with impaired renal
function: Insights from the ABOARD Study.
Source
International Journal of Cardiology. 167 (6) (pp 2646-2652), 2013. Date of
Publication: 2013.
Publisher
Elsevier Ireland Ltd (P.O. Box 85, Limerick, Ireland)
Abstract
Background: To assess the impact of impaired renal function (IRF) and
timing of catheterization (immediate versus delayed intervention) on
outcomes in intermediate/high risk NSTE-ACS patients. Methods: We
performed a post-hoc analysis of the randomized ABOARD population to
compare 1) patients with vs. without IRF and 2) the two intervention
strategies in patients with IRF. A creatinine clearance < 60 mL/min
defined IRF. The primary endpoint was the in-hospital peak troponin I
value; the secondary endpoints were a) the composite of death, myocardial
infarction, urgent revascularization or recurrent ischemia
(death/MI/UR/RI) and b) STEEPLE major bleeding (MB) at 1-month follow-up.
Results: Among the 345 patients, 75 (21.7%) had IRF. Patients with IRF
were older, had more comorbidities and were at higher cardiovascular risk.
Radial catheterization was predominant (84%). Among IRF patients, 37 (49%)
and 38 (51%) patients were randomized to an immediate and delayed
strategy, respectively. The primary and secondary endpoints rates were not
different for the two comparisons. IRF was associated with more death
(5.3% vs. 1.1%, p = 0.043) and non-CABG MB (9.3% vs. 2.2%, p = 0.001). In
patients with IRF, a delayed strategy was associated with more recurrent
ischemia (28.9% vs. 8.1%, p = 0.021). Absence of clopidogrel pretreatment,
insulin therapy and left main culprit lesion were independently associated
with death/MI/UR/RI, while age and CABG surgery were related with MB.
Conclusion: IRF is associated with worse outcomes in NSTE-ACS patients.
The primary results of the ABOARD study apply also to patients with IRF in
which the timing of catheterization does not impact hard outcomes. 2012
Elsevier Ireland Ltd.

<19>
Accession Number
2013603552
Authors
Yu G.-P. Shen Z.-Y.
Institution
(Yu, Shen) Department of Cardiothoracic Vascular Surgery, Affiliated
Jiangyin Hospital of Medical School, Southeast University, Jiangyin
214400, Jiangsu Province, China
Title
Research advances in mechanisms by which bone marrow stem cells improve
myocardial function.
Source
Chinese Journal of Tissue Engineering Research. 16 (41) (pp 7747-7751),
2012. Date of Publication: 2012.
Publisher
Journal of Clinical Rehabilitative (P.O. Box 1200, Shenyang 110004, China)
Abstract
Background: Bone marrow mesenchymal stem cells transplantation can
significantly improve the cardiac structure reconfiguration and cardiac
function through affecting the myocardial cell formation and myocardial
angiogenesis. Objective: To summarize the theoretical basis of bone marrow
mesenchymal stem cells transplantation for the treatment of ischemic
cardomyopathy through researching the effect of bone marrow mesenchymal
stem cells transplantation on myocardial function. Methods: The Chinese
Biomedical Literature database and Medline database from 1994 to 2011 were
used to search the reviews and reports that relate to the application of
bone marrow mesenchymal stem cells transplantation for the treatment of
ischemic cardomyopathy, and the research progress was analyzed. Results
and Conclusion: A total of 37 articles were included for the review.
Autologous application of bone marrow mesenchmal stem cells
transplantation can be amplified in vitro without immune rejection and can
avoid the ethical controversy. Research of bone marrow stem cells for the
treatment of acute myocardial infarction is still in the early stage. With
the development of the research, bone marrow mesenchymal stem cells become
a new method for the treatment of ischemic cardiomyopathy if we can find
an effective and safe dosage.